Literature DB >> 18303478

Promising novel cytotoxic agents and combinations in metastatic prostate cancer.

Deborah A Bradley1, Maha Hussain.   

Abstract

Interest in investigating cytotoxic therapy has increased dramatically since a survival advantage was demonstrated in 2 phase III trials investigating docetaxel-based therapy in hormone-refractory prostate cancer. This result led to an expansion in research in this area with several ongoing trials evaluating docetaxel-based combinations and new cytotoxic agents.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18303478     DOI： 10.1097/PPO.0b013e31816220b7

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  5 in total

1.  Diffuse primary leptomeningeal melanocytosis in a patient receiving a novel cancer cell vaccine for prostate cancer.

Authors:  Benedict Daniel Michael; Isabel Syndikus; Alistair Clark; Atik Baborie
Journal:  BMJ Case Rep       Date:  2010-05-04

2.  Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer.

Authors:  Asa Jellvert; Ingela Franck Lissbrant; Maliha Edgren; Elisabeth Ovferholm; Karin Braide; Ann-Marie Ekelund Olvenmark; Jon Kindblom; Per Albertsson; Bo Lennernäs
Journal:  Exp Ther Med       Date:  2011-05-12       Impact factor: 2.447

Review 3.  Immunotherapy for prostate cancer: an emerging treatment modality.

Authors:  Charles G Drake
Journal:  Urol Clin North Am       Date:  2010-02       Impact factor: 2.241

4.  A model of toxic neuropathy in Drosophila reveals a role for MORN4 in promoting axonal degeneration.

Authors:  Martha R C Bhattacharya; Josiah Gerdts; Sarah A Naylor; Emily X Royse; Sarah Y Ebstein; Yo Sasaki; Jeffrey Milbrandt; Aaron DiAntonio
Journal:  J Neurosci       Date:  2012-04-11       Impact factor: 6.167

5.  The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.

Authors:  Yogesh B Patil; Suresh K Swaminathan; Tanmoy Sadhukha; Linan Ma; Jayanth Panyam
Journal:  Biomaterials       Date:  2009-10-01       Impact factor: 12.479
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.